CN1907271A - Selegilne and/or chlorhydric acid selegilne paste matrix and preparation method for said paste - Google Patents
Selegilne and/or chlorhydric acid selegilne paste matrix and preparation method for said paste Download PDFInfo
- Publication number
- CN1907271A CN1907271A CN 200610010454 CN200610010454A CN1907271A CN 1907271 A CN1907271 A CN 1907271A CN 200610010454 CN200610010454 CN 200610010454 CN 200610010454 A CN200610010454 A CN 200610010454A CN 1907271 A CN1907271 A CN 1907271A
- Authority
- CN
- China
- Prior art keywords
- selegilinehydrochloride
- selegiline
- patch
- patch substrate
- adhesive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a Slagilan and or alcaine Slagilan attaching agent base and preparing method, which comprises the following parts: Slagilan and or alcaine Slagilan, adhesive and organic solvent. The preparing method comprises the following steps: (1) coating compound of raw materials on the back lining evenly; (2) drying; covering the protective film on the other surface of attaching base to obtain the product.
Description
Technical field
The present invention relates to the preparation method of a kind of patch substrate and patch thereof.
Background technology
Transdermal drug delivery system (tranderma[therapeuticsystems, TTS) be to make medicine constant speed (or near constant speed) enter blood and not in subcutaneous accumulations by skin in the skin surface administration, these are different with the preparation (as ointment, plaster, varnish and aerosol etc.) that plays a role in skin or subcutaneous local organization, have the following advantages: (1) avoids contingent liver first-pass effect of oral administration and the intestines and stomach deactivation, improve therapeutic effect, reduced toxicity; When the skin administration, medicine can continue to diffuse into blood circulation for a long time.(2) the control medicine enters human circulation near constant release, gives full play to the therapeutical effect of medicine, absorbs steadily relatively, has avoided other preparation the blood drug level peak valley undulatory property and the consequent toxic and side effects of time medication appearance more than a day.(3) prolong action time, reduce administration number of times, strengthen patient's compliance.(4) independently medication of patient, also drug withdrawal at any time, medicine can tear off from skin surface with TTS, and stops administration.(5) TTS be can't oral administration the patient, especially vomiting and diarrhea patient provide a kind of alternative route.And TTS is the non-invasi administration, the inconvenience of avoiding drug administration by injection to bring.
Selegiline and SelegilineHydrochloride are the medicines with direct stimulation, antidepressant and inhibition monoamine oxidase, MAO (MAOI) effect.Monoamine oxidase A (MAO-A) and monoamine oxidase-B (MAO-B) are the enzymes that central nervous system is unified and found in the surrounding tissue.The oxidative deamination of MAO-A and MAO-B catalysis primary amine (comprising neural activity and vasoactive amines) causes the placed in-line formation of toxicity radical type material and free-radical generating.Evidence suggests that selegiline and SelegilineHydrochloride can provide neuroprotective or neuron reparation by alleviating the oxidative damage that is caused by monoamine oxidase, MAO and/or other oxidant.The existing preparation of selegiline and SelegilineHydrochloride is usually used in treating Parkinson's disease.Major depressive disorder is a kind of common mental symptom in modern crowd.Depressive symptom comprises that general emotion is dejected, withdrawal (withdrawal) and uneasiness; it has disturbed daily function; as: to usual active hebetude; the great change of body weight and/or appetite; insomnia, tired increase, feeling of guilt and inferiority complex; slowness of thinking or absent minded, and certain suicidal attempt or suicidal idea (ideation).Though oral selegiline or SelegilineHydrochloride can suppress the activity of monoamine oxidase, MAO (MAOI), but because MAO-A participates in the digestion process of some F﹠B such as tyramine, if the activity inhibited of MAO-A, a large amount of tyramines can be absorbed, blood pressure can raise suddenly significantly, is called " hypertensive crisis " (hypertentive crisis).Hypertensive crisis may cause apoplexy and death.So when taking selegiline or SelegilineHydrochloride, the doctor can advise that the patient controls feed, foods such as the edible beer on draft that is rich in tyramine, red wine, Semen Viciae fabae, salami (salamis), old cheese, soy sauce.
Summary of the invention
The objective of the invention is the problem that need keep on a diet when solving present oral selegiline or SelegilineHydrochloride medicine, and the preparation method of a kind of selegiline that provides and/or SelegilineHydrochloride patch substrate and patch thereof.Selegiline and/or SelegilineHydrochloride patch substrate comprise selegiline and/or SelegilineHydrochloride, adhesive and organic solvent; Selegiline and/or SelegilineHydrochloride account for 0.5%～40% of patch substrate quality, and adhesive accounts for 10%～90% of patch substrate quality, and surplus is an organic solvent; Wherein organic solvent is one or more compositions in ethyl acetate, ethanol, acetone, the propylene glycol.Aforesaid selegiline and/or SelegilineHydrochloride patch prepare according to the following steps: (one) will account for behind the organic solvent mix homogeneously of the selegiline and/or the SelegilineHydrochloride of patch substrate quality 0.5%～40%, the adhesive that accounts for patch substrate quality 10%～90% and surplus evenly on the coating backing layer, and the patch substrate of every square centimeter of surface area contains selegiline and/or SelegilineHydrochloride 0.1～10mg; (2) after drying under 20～80 ℃ of conditions, the protectiveness thin film is covered another surface of patch substrate, promptly obtain selegiline and/or SelegilineHydrochloride patch.Selegiline of the present invention and/or SelegilineHydrochloride patch be by the skin surface administration, enters blood and not in subcutaneous accumulations, area is 10～60cm
2Patch substrate medicine every day to pass the medicine rate be 2～20mg.Selegiline of the present invention and/or SelegilineHydrochloride patch have: (1) avoids contingent liver first-pass effect of oral administration and the intestines and stomach deactivation, has improved therapeutic effect, no toxicity; When the skin administration, medicine can continue to diffuse into blood circulation for a long time; (2) the control medicine enters human circulation near constant release, gives full play to the therapeutical effect of medicine, absorbs steadily relatively, has avoided other preparation the blood drug level peak valley undulatory property and the consequent toxic and side effects of time medication appearance more than a day; (3) prolong action time, reduce administration number of times, strengthen patient's compliance; (4) independently medication of patient, also drug withdrawal at any time, medicine can tear off from skin surface with patch, and stops administration; (5) can be can't oral administration the patient, especially vomiting and diarrhea patient provide a kind of alternative route; (6) advantage such as needn't keep on a diet during the medication.Selegiline of the present invention and/or SelegilineHydrochloride patch preparation method are simple, are convenient to operation.
The specific embodiment
The specific embodiment one: present embodiment selegiline and/or SelegilineHydrochloride patch substrate are made by selegiline and/or SelegilineHydrochloride, adhesive and organic solvent; Selegiline and/or SelegilineHydrochloride account for 0.5%～40% of patch substrate quality, and adhesive accounts for 10%～90% of patch substrate quality, and surplus is an organic solvent; Wherein organic solvent is one or more compositions in ethyl acetate, ethanol, acetone, the propylene glycol.
Present embodiment selegiline and/or SelegilineHydrochloride patch substrate and skin have the good compatibility and adhesiveness, long-term stable experiment proves that significant change does not all take place for active component content, release in vitro degree and the adhesion characteristics of this substrate, shows that this substrate has good stable.
The specific embodiment two: the difference of the present embodiment and the specific embodiment one is: selegiline and/or SelegilineHydrochloride patch substrate also comprise the plasticizer that accounts for patch substrate quality 0.1%～20%, 0.1%～20% viscosifier, 0.1%～20% Percutaneous absorption enhancer and/or 0.1%～10% crystallization inhibitor.Other is identical with embodiment one.
Area is 10～60cm in the present embodiment
2Patch substrate medicine every day to pass the medicine rate be 5～18mg.
The specific embodiment three: the difference of the present embodiment and the specific embodiment one is: adhesive is polyisobutylene class pressure sensitive adhesive, silicone rubber kinds pressure sensitive adhesive, polyacrylate pressure-sensitive or acrylate pressure sensitive adhesive.Other is identical with embodiment one.
The specific embodiment four: the difference of the present embodiment and the specific embodiment two is: plasticizer is one or more compositions in mineral oil, low-molecular-weight Polyethylene Glycol, propylene glycol, glycerol, the triethyl citrate.Other is identical with embodiment two.
Plasticizer in the present embodiment can concern for arbitrary proportion between each component if be made up of two or more material.
The specific embodiment five: the difference of the present embodiment and the specific embodiment two is: plasticizer is glycerol and triethyl citrate.Other is identical with embodiment two.
The specific embodiment six: the difference of the present embodiment and the specific embodiment two is: plasticizer is a mineral oil.Other is identical with embodiment two.
The specific embodiment seven: the difference of the present embodiment and the specific embodiment two is: plasticizer is a low molecular poly.Other is identical with embodiment two.
The specific embodiment eight: the difference of the present embodiment and the specific embodiment two is: viscosifier are one or more compositions in terpene resin, Colophonium, the Foral.Other is identical with embodiment two.
Viscosifier in the present embodiment can concern for arbitrary proportion between each component if be made up of two or more material.
The specific embodiment nine: the difference of the present embodiment and the specific embodiment two is: viscosifier are terpene resin and Colophonium.Other is identical with embodiment two.
The specific embodiment ten: the difference of the present embodiment and the specific embodiment two is: viscosifier are Colophonium and Foral.Other is identical with embodiment two.
The specific embodiment 11: the difference of the present embodiment and the specific embodiment two is: Percutaneous absorption enhancer is one or more compositions in oleic acid, N-Methyl pyrrolidone, Polyethylene Glycol, propylene glycol, laurocapram, glyceryl triacetate, Oleum menthae, the eucalyptus oil.Other is identical with embodiment two.
Percutaneous absorption enhancer in the present embodiment can concern for arbitrary proportion between each component if be made up of two or more material.
The specific embodiment 12: the difference of the present embodiment and the specific embodiment two is: Percutaneous absorption enhancer is N-Methyl pyrrolidone, Polyethylene Glycol, propylene glycol, laurocapram, glyceryl triacetate and Oleum menthae.Other is identical with embodiment two.
The specific embodiment 13: the difference of the present embodiment and the specific embodiment two is: Percutaneous absorption enhancer is an eucalyptus oil.Other is identical with embodiment two.
The specific embodiment 14: the difference of the present embodiment and the specific embodiment two is: Percutaneous absorption enhancer is eucalyptus oil and Oleum menthae.Other is identical with embodiment two.
The specific embodiment 15: the difference of the present embodiment and the specific embodiment two is: crystallization inhibitor is soluble poly vinylpyrrolidone, Polyethylene Glycol, polypropylene glycol, glycerol or silicon dioxide.Other with
Embodiment two is identical.
The specific embodiment 16: the difference of the present embodiment and the specific embodiment one is: SelegilineHydrochloride accounts for 0.5%～40% of patch substrate quality in the patch substrate.Other is identical with embodiment one.
The specific embodiment 17: the difference of the present embodiment and the specific embodiment one is: SelegilineHydrochloride and selegiline account for 0.5%～40% of patch substrate quality in the patch substrate.Other is identical with embodiment one.
Can be arbitrary proportion between SelegilineHydrochloride and the selegiline in the present embodiment.
The specific embodiment 18: the difference of the present embodiment and the specific embodiment one is: selegiline and/or SelegilineHydrochloride account for 5%～35% of patch substrate quality.Other is identical with embodiment one.
The specific embodiment 19: the difference of the present embodiment and the specific embodiment one is: selegiline and/or SelegilineHydrochloride account for 10%～30% of patch substrate quality.Other is identical with embodiment one.
The specific embodiment 20: the difference of the present embodiment and the specific embodiment one is: selegiline and/or SelegilineHydrochloride account for 15%～25% of patch substrate quality.Other is identical with embodiment one.
The specific embodiment 21: the difference of the present embodiment and the specific embodiment three is: acrylate pressure sensitive adhesive is by acrylic acid, acrylic amine, hexyl acrylate, acrylic acid 2-ethylhexyl ester, hydroxyethyl acrylate, 1-Octyl acrylate, butyl acrylate, acrylic acid methyl ester., glycidyl acrylate, methacrylic acid, Methacrylamide, acrylic acid is the ylmethyl ester, methacrylic acid 2-ethylhexyl ester, 2-Propenoic acid, 2-methyl-, octyl ester, methyl methacrylate, glycidyl methacrylate, vinyl acetate, two or more material is made in the vinylpyrrolidone.Other is identical with embodiment three.
Acrylate pressure sensitive adhesive is made by two or more material in the present embodiment, can concern for arbitrary proportion between each component.Acrylate pressure sensitive adhesive in the present embodiment is by existing processes well known preparation.
The specific embodiment 22: the difference of the present embodiment and the specific embodiment three is: polyisobutylene class pressure sensitive adhesive is made by polyisobutylene.Other is identical with embodiment three.
Can concern for arbitrary proportion between the polyisobutylene of each molecular weight in the present embodiment.Polyisobutylene class pressure sensitive adhesive in the present embodiment is by existing processes well known preparation.
The specific embodiment 23: the difference of the present embodiment and the specific embodiment three is: the silicone rubber kinds pressure sensitive adhesive is made by two or more material in silicone resin, silicone natural gum, the polydimethylsiloxane.Other is identical with embodiment three.
The silicone rubber kinds pressure sensitive adhesive is made by two or more material in the present embodiment, can concern for arbitrary proportion between each component.Silicone rubber kinds pressure sensitive adhesive in the present embodiment is by existing processes well known preparation.
The specific embodiment 24: the difference of the present embodiment and the specific embodiment three is: polyacrylate pressure-sensitive is made by two or more material in acrylic acid of polymerization-grade, high purity acrylic acid, acrylic acid methyl ester., ethyl acrylate, butyl acrylate, 2-ethylhexyl acrylate, 2-ethoxy acrylic acid, vinyl acetate, methacrylic acid, butylacrylic acid, methacrylic acid dehydration glyceride, the acid of polyoxyethylene nonyl.Other is identical with embodiment three.
Polyacrylate pressure-sensitive is made by two or more material in the present embodiment, can concern for arbitrary proportion between each component.Polyacrylate pressure-sensitive in the present embodiment is by existing processes well known preparation.
The specific embodiment 25: present embodiment selegiline and/or SelegilineHydrochloride patch substrate are made by 100 parts of Polyisobutylene PSA, 40 parts of acetone and 5 parts of selegilines by weight.
The specific embodiment 26: present embodiment selegiline and/or SelegilineHydrochloride patch substrate are made by 100 parts of acrylate pressure sensitive adhesives, 20 parts of acetone-ethanol (1: 1), 5 parts of SelegilineHydrochlorides, 1 part of oleic acid and 1 part of silicon dioxide by weight.
The specific embodiment 27: present embodiment selegiline and/or SelegilineHydrochloride patch substrate are by weight by 90 parts of polyacrylate pressure-sensitives, and 20 parts of ethanol, 10 parts of SelegilineHydrochlorides, 8 parts of propylene glycol, 3 parts of glyceryl triacetate and 1 part of laurocapram are made.
The specific embodiment 28: the difference of the present embodiment and the specific embodiment one is: organic solvent is made up of ethyl acetate and acetone.Other is identical with embodiment one.
Ethyl acetate and acetone can concern for arbitrary proportion in the present embodiment organic solvent.
The specific embodiment 29: present embodiment prepares the patch that contains the specific embodiment one selegiline and/or SelegilineHydrochloride patch substrate according to the following steps: (one) will account for behind the organic solvent mix homogeneously of the selegiline and/or the SelegilineHydrochloride of patch substrate quality 0.5%～40%, the adhesive that accounts for patch substrate quality 10%～90% and surplus evenly on the coating backing layer, and the patch substrate of every square centimeter of surface area contains selegiline and/or SelegilineHydrochloride 0.1～10mg; (2) after drying under 20～80 ℃ of conditions, the protectiveness thin film is covered another surface of patch substrate, promptly obtain selegiline and/or SelegilineHydrochloride patch.
Backing layer can be non-woven fabrics, elastic force cloth, clad aluminum foil, polyester film, paper, polychloroethylene film, polyethylene film, polypropylene screen or polyethylene terephthalate in the present embodiment.The protectiveness thin film can be siliconised paper, polyethylene film, polystyrene film, polypropylene screen, polycarbonate membrane or poly tetrafluoroethylene in the present embodiment.
It is 5～60cm that the selegiline of present embodiment preparation and/or SelegilineHydrochloride patch cut into area
2Tetragon or circle promptly obtain finished product selegiline and/or SelegilineHydrochloride patch.
Selegiline and/or SelegilineHydrochloride patch with the present embodiment preparation carry out the transdermal test in vitro test:
(1) peel off the skin of rat (Kunming mouse) that has just die and the people who has just passed away and remove subcutaneous fat, normal saline is cleaned the back freezing and is stored standby;
(2) getting area is 2.3127cm
2TTS be separately fixed on the standby rat skin of previous step, adopt Franz transdermal diffusion cell to carry out the transdermal test, 32 ℃ of bath temperatures, mixing speed 300rpm, reception tank volume 6mL receives liquid for containing 30% alcoholic acid normal saline solution.Get whole samples respectively at 3,6,9,12,24,48 hours, change synthermal blank and receive liquid with volume.Sample adopts high performance liquid chromatography to analyze; Getting area is 2.3127cm
2TTS be separately fixed at the standby people of previous step and exsomatize on the skin of chest, adopt Franz transdermal diffusion cell to carry out the transdermal test, 32 ℃ of bath temperatures, mixing speed 300rpm, reception tank volume 6mL receives liquid for containing 30% alcoholic acid normal saline solution.Get whole samples respectively at 3,6,9,12,24,48,72,96 hours, change synthermal blank and receive liquid with volume.Sample adopts high performance liquid chromatography, and (chromatographic condition is an immobile phase; C
18Mobile phase: 800 portions of 0.1mol/L Ammonium biphosphate buffer, PH3.1,200 parts of acetonitriles; Detect wavelength: 210nm; Flow velocity: 1.0mL/min; Column temperature: room temperature) analyze.Result of the test sees Table 1.
Table 1
| Selegiline and/or SelegilineHydrochloride content (mg) | Average accumulated transdermal amount (μ g/cm 2) | ||||
| 24 hours | 48 hours | 72 hours | 96 hours | ||
| Rat skin (n=6 group) | 20.0 | 457.6 | 846.7 | 1367.5 | 1787.9 |
| People's isolated skin (n=6 group) | 20.0 | 304.2 | 617.6 | 939.6 | 1208.5 |
The result shows that selegiline that the present invention prepares and/or SelegilineHydrochloride patch can see through rat skin and people's isolated skin effectively, in large quantities, and its transdermal amount at people's isolated skin is about 300 μ g/cm every day
2, and this product release that in the test that continues 96 hours, can keep constant speed, homogeneous all the time, there is not the prominent phenomenon of releasing.
The selegiline and/or the SelegilineHydrochloride patch of the present invention's preparation are applied to trunk top (more than the following waist of neck), thigh top or the outside drying of upper limb, complete skin.Every subsides patch can use 1～4 day, and drug effect is continual and steady.
The selegiline and/or the SelegilineHydrochloride patch of the present invention's preparation are treated 100 adult patients that suffer from depression, 100 patient treatments are evident in efficacy after 25 days, studies have shown that the selegiline of the present invention's preparation and/or the safety and the effectiveness of SelegilineHydrochloride patch treatment severe depression obstacle in 6～8 weeks that patients with depression is carried out and long-term follow treatment.The patient who is diagnosed as adult's depression by the DSM-IV standard has carried out the test in 10 weeks by a definite date, has 48% to use the patient of placebo treatment to withdraw from test before the off-test in 10 weeks in the test, withdraws from former because the depression recurrence.The test of cure effect is estimated by 17 standards of HAM-D, and the patient has scoring all less than 10 when 8 weeks, 9 weeks and 10 weeks.In test, recurrence is defined as: (1) presses 17 standard evaluation score 〉=14 of HAM-D; (2) by CGI-S standard scoring 〉=3 (compare have at least two indexs to increase with basic data before the test); And after off-test, diagnose by adult's depression DSM-VI standard, blanking time greater than 11 days the double consultation of doctors in, use patient's relapse rate of TTS of the present invention lower more than 20% continuously, and morbidity is longer more than 30% than the patient who uses placebo treatment blanking time than the patient who uses placebo treatment.
Use the side effect of the selegiline of the present invention's preparation and/or SelegilineHydrochloride patch to have patch location for paste skin that slight general red, blood pressure drops or slight headache are arranged; 1～2 day symptom disappears automatically after the drug withdrawal.The careful usefulness of child or teenager.
The specific embodiment 30: the difference of the present embodiment and the specific embodiment 29 is: will account for plasticizer, 0.1%～20% viscosifier, 0.1%～20% the Percutaneous absorption enhancer of patch substrate quality 0.1%～20% and/or 0.1%～10% crystallization inhibitor and selegiline and/or SelegilineHydrochloride, adhesive and organic solvent in the step () together behind the mix homogeneously evenly on the coating backing layer.Other step is identical with embodiment 29.
Specific embodiment hentriaconta-: the difference of the present embodiment and the specific embodiment 29 is: backing layer is non-woven fabrics, elastic force cloth, clad aluminum foil, polyester film, paper, polychloroethylene film, polyethylene film, polypropylene screen or polyethylene terephthalate.Other step is identical with embodiment 29.
The specific embodiment 32: the difference of the present embodiment and the specific embodiment 29 is: the protectiveness thin film is siliconised paper, polyethylene film, polystyrene film, polypropylene screen, polycarbonate membrane or poly tetrafluoroethylene.Other step is identical with embodiment 29.
Claims (10)
1, selegiline and/or SelegilineHydrochloride patch substrate is characterized in that selegiline and/or SelegilineHydrochloride patch substrate comprise selegiline and/or SelegilineHydrochloride, adhesive and organic solvent; Selegiline and/or SelegilineHydrochloride account for 0.5%～40% of patch substrate quality, and adhesive accounts for 10%～90% of patch substrate quality, and surplus is an organic solvent; Wherein organic solvent is one or more compositions in ethyl acetate, ethanol, acetone, the propylene glycol.
2, selegiline according to claim 1 and/or SelegilineHydrochloride patch substrate is characterized in that selegiline and/or SelegilineHydrochloride patch substrate also comprise the plasticizer that accounts for patch substrate quality 0.1%～20%, 0.1%～20% viscosifier, 0.1%～20% Percutaneous absorption enhancer and/or 0.1%～10% crystallization inhibitor.
3, selegiline according to claim 1 and/or SelegilineHydrochloride patch substrate is characterized in that adhesive is polyisobutylene class pressure sensitive adhesive, silicone rubber kinds pressure sensitive adhesive, polyacrylate pressure-sensitive or acrylate pressure sensitive adhesive.
4, selegiline according to claim 2 and/or SelegilineHydrochloride patch substrate is characterized in that plasticizer is one or more compositions in mineral oil, low-molecular-weight Polyethylene Glycol, propylene glycol, glycerol, the triethyl citrate.
5,, it is characterized in that viscosifier are one or more compositions in terpene resin, Colophonium, the Foral according to described selegiline of claim 2 and/or SelegilineHydrochloride patch substrate.
6,, it is characterized in that Percutaneous absorption enhancer is one or more compositions in oleic acid, N-Methyl pyrrolidone, Polyethylene Glycol, propylene glycol, laurocapram, glyceryl triacetate, Oleum menthae, the eucalyptus oil according to described selegiline of claim 2 and/or SelegilineHydrochloride patch substrate.
7,, it is characterized in that crystallization inhibitor is soluble poly vinylpyrrolidone, Polyethylene Glycol, polypropylene glycol, glycerol or silicon dioxide according to described selegiline of claim 2 and/or SelegilineHydrochloride patch substrate.
8, selegiline according to claim 1 and/or SelegilineHydrochloride patch substrate is characterized in that SelegilineHydrochloride accounts for 0.5%～40% of patch substrate quality in the patch substrate.
9, a kind ofly contain the preparation method that right requires the patch of 1 described selegiline and/or SelegilineHydrochloride patch substrate, it is characterized in that selegiline and/or SelegilineHydrochloride patch prepare according to the following steps: (one) will account for behind the organic solvent mix homogeneously of the selegiline and/or the SelegilineHydrochloride of patch substrate quality 0.5%～40%, the adhesive that accounts for patch substrate quality 10%～90% and surplus evenly on the coating backing layer, and the patch substrate of every square centimeter of surface area contains selegiline and/or SelegilineHydrochloride 0.1～10mg; (2) after drying under 20～80 ℃ of conditions, the protectiveness thin film is covered another surface of patch substrate, promptly obtain selegiline and/or SelegilineHydrochloride patch.
10, the preparation method of selegiline according to claim 9 and/or SelegilineHydrochloride patch is characterized in that will accounting in the step () that plasticizer, 0.1%～20% viscosifier, 0.1%～20% the Percutaneous absorption enhancer of patch substrate quality 0.1%～20% and/or 0.1%～10% crystallization inhibitor and selegiline and/or SelegilineHydrochloride, adhesive and organic solvent are together behind the mix homogeneously evenly on the coating backing layer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610010454 CN1907271A (en) | 2006-08-29 | 2006-08-29 | Selegilne and/or chlorhydric acid selegilne paste matrix and preparation method for said paste |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610010454 CN1907271A (en) | 2006-08-29 | 2006-08-29 | Selegilne and/or chlorhydric acid selegilne paste matrix and preparation method for said paste |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1907271A true CN1907271A (en) | 2007-02-07 |
Family
ID=37698610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200610010454 Pending CN1907271A (en) | 2006-08-29 | 2006-08-29 | Selegilne and/or chlorhydric acid selegilne paste matrix and preparation method for said paste |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1907271A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102188410A (en) * | 2010-03-12 | 2011-09-21 | 日东电工株式会社 | Selegiline-containing adhesive preparation |
| CN104000803A (en) * | 2014-06-16 | 2014-08-27 | 成都厚生药物研究开发有限公司 | Scapulohumeral periarthritis patch and preparation method thereof |
| CN116077419A (en) * | 2023-02-24 | 2023-05-09 | 丽珠集团新北江制药股份有限公司 | Selaginella hydrochloride Ji Lantou skin absorbent for dogs and preparation method thereof |
-
2006
- 2006-08-29 CN CN 200610010454 patent/CN1907271A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102188410A (en) * | 2010-03-12 | 2011-09-21 | 日东电工株式会社 | Selegiline-containing adhesive preparation |
| EP2371360A3 (en) * | 2010-03-12 | 2012-04-18 | Nitto Denko Corporation | Selegiline-containing adhesive preparation |
| CN104000803A (en) * | 2014-06-16 | 2014-08-27 | 成都厚生药物研究开发有限公司 | Scapulohumeral periarthritis patch and preparation method thereof |
| CN116077419A (en) * | 2023-02-24 | 2023-05-09 | 丽珠集团新北江制药股份有限公司 | Selaginella hydrochloride Ji Lantou skin absorbent for dogs and preparation method thereof |
| CN116077419B (en) * | 2023-02-24 | 2023-10-27 | 丽珠集团新北江制药股份有限公司 | Selaginella hydrochloride Ji Lantou skin absorbent for dogs and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3179989B1 (en) | Silicone-containing acrylic polymers for transdermal drug delivery compositions | |
| CN1240384C (en) | Transdermal administration of huperzine | |
| KR101454362B1 (en) | Percutaneous absorption preparations for the treatment of dementia containg donepezil as an active ingredient | |
| JP5899243B2 (en) | Donepezil transdermal patch | |
| US5122383A (en) | Sorbitan esters as skin permeation enhancers | |
| US10660863B2 (en) | Transdermal therapeutic system for administering an active substance | |
| CN102413821A (en) | Transdermal preparation | |
| JP6793648B2 (en) | Transdermal preparation containing donepezil as an active ingredient | |
| US5227169A (en) | Sorbitan esters as skin permeation enhancers | |
| DE69916492T3 (en) | PLASTER FOR THE TRANSDERMAL APPLICATION OF VOLATILE, LIQUID ACTIVE SUBSTANCES | |
| CN1232389A (en) | Patch | |
| JPH06503576A (en) | Methods and systems for transdermally administering drugs using sorbitan esters as skin penetration enhancers | |
| CN1942207A (en) | Crosslinkable skin care adhesive | |
| KR20120001844A (en) | Transdermal drug delivery system comprising donepezil | |
| CN1450883A (en) | Transdermal delivery system for alkaloids of aconitum species | |
| RU2004131866A (en) | FORM OF TRANSEPICUTAL INTRODUCTION FOR TREATMENT OF TIRED FOOT SYNDROME | |
| CN1839796A (en) | Tape preparation | |
| US20090203797A1 (en) | Antimycotic Patch | |
| KR20000065244A (en) | Transdermal Dose Propenephylline Composition for Alzheimer's Disease | |
| CN1805739A (en) | Anti-inflammatory analgesic adhesive patch | |
| CN1907271A (en) | Selegilne and/or chlorhydric acid selegilne paste matrix and preparation method for said paste | |
| JPH10512245A (en) | Compositions and methods for transdermal delivery of acid labile drugs | |
| CN1927190A (en) | Letrozole transdermal drug administration plaster and its preparation method | |
| CN1927191A (en) | Lornoxicam transdermal drug administration plaster and its preparation method | |
| HUE035512T2 (en) | Pharmaceutical patch for transdermal administration of tapentadol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |